17.06.2013 • News

PVC Producer Kem One Says Business is Back to Normal

In an update on its current business situation, insolvent PVC producer Kem One - the spun-off Arkema business - said production has returned to near-normal levels at all of its plants, following the resumption of ethylene supply.

As part of a compromise agreement in the long-running dispute between the company's former owner Arkema and its current owner, Swiss-based Klesch, over the state of the business's finances at the time of acquisition a year ago, the insolvency administrator asked Arkema's parent, French oil and petrochemical producer Total, to continue ethylene supply at a rebate against the contract reference price.

Noting that the insolvency proceedings initially due to be concluded in mid-June are "on schedule," Kem One - without naming names - hinted that "several potential buyers" have shown interest in the company. Also without naming names, it added that the financial situation is improving, thanks to the support pledged for the duration of the proceedings.

Arkema had promised the insolvency administrator and the French government to contribute €68 million to keep the PVC producer afloat until a new owner has been found. In April, reports said €105 million was regarded as necessary to keep production going for a six-month period.

Kem One also praised its customers for their confidence and employees for their dedication. The entire workforce is committed not only to maintaining a high level of customer service but also to finding sustainable solutions for the group, it said. Earlier this year, the company's unions made headlines by setting tires afire in front of production facilities and corporate headquarters.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.